Applicant, as named in the Orange Book
Takeda Pharms Am
Takeda Pharmaceutical Co Ltd · NYSE: TAK
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Mimrylo on 17 Mar 2034. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Mimrylo NDA 220605 · 5 strengths rusfertide acetate | 17 Mar 2034 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.